Bibliographic Details
| Title: |
Advancing Evidence Generation for Circulating Tumor DNA: Lessons Learned from A Multi-Assay Study of Baseline Circulating Tumor DNA Levels across Cancer Types and Stages. |
| Authors: |
McKelvey, Brittany A., Andrews, Hillary S., Baehner, Frederick L., Chen, James, Espenschied, Carin R., Fabrizio, David, Gorton, Vanessa, Gould, Claire, Guinney, Justin, Jones, Greg, Lv, Xiangyang, Nahorski, Michael S., Palomares, Melanie R., Pestano, Gary A., Sausen, Mark, Silk, Alain, Zhang, Nicole, Zhang, Zhihong, Stewart, Mark D., Allen, Jeff D. |
| Source: |
Diagnostics (2075-4418); May2024, Vol. 14 Issue 9, p912, 9p |
| Subject Terms: |
CIRCULATING tumor DNA, NON-small-cell lung carcinoma, TUMOR classification, HEAD & neck cancer |
| Abstract: |
Circulating tumor DNA (ctDNA) holds promise as a biomarker for predicting clinical responses to therapy in solid tumors, and multiple ctDNA assays are in development. However, the heterogeneity in ctDNA levels prior to treatment (baseline) across different cancer types and stages and across ctDNA assays has not been widely studied. Friends of Cancer Research formed a collaboration across multiple commercial ctDNA assay developers to assess baseline ctDNA levels across five cancer types in early- and late-stage disease. This retrospective study included eight commercial ctDNA assay developers providing summary-level de-identified data for patients with non-small cell lung cancer (NSCLC), bladder, breast, prostate, and head and neck squamous cell carcinoma following a common analysis protocol. Baseline ctDNA levels across late-stage cancer types were similarly detected, highlighting the potential use of ctDNA as a biomarker in these cancer types. Variability was observed in ctDNA levels across assays in early-stage NSCLC, indicative of the contribution of assay analytical performance and methodology on variability. We identified key data elements, including assay characteristics and clinicopathological metadata, that need to be standardized for future meta-analyses across multiple assays. This work facilitates evidence generation opportunities to support the use of ctDNA as a biomarker for clinical response. [ABSTRACT FROM AUTHOR] |
|
Copyright of Diagnostics (2075-4418) is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
|
Full text is not displayed to guests. |
Login for full access.
|
